Downloads

You can engage with new prospects by sponsoring a download on Drug Discovery Today. Downloads provide users with the option to review the information as frequently as they need so it's an ideal way to share those white-papers. Our easy-to-use registration process provides you with a list of pre-qualified leads.

To find out more about how you can be involved with downloads on this website contact us today.

Download Now

Non-coding RNAs and new opportunities for the private sector

Fabrício F. Costa argues that the private sector should start paying more attention to non-coding RNAs to improve the pipeline for drug discovery and drug development and to facilitate the identification of new diagnostic and prognostic markers.
23 August 2010

Targeted genetic and viral therapy for advanced head and neck cancers

Head and neck cancers usually present with advanced disease, and novel therapies are urgently needed. Here, Pin-I Huang, Ju-Fang Chang, David H. Kirn and Ta-Chiang Liu summarize the available clinical data and discuss challenges and future directions.
20 August 2010

siRNAs: their potential as therapeutic agents – Part II. Methods of delivery

Sunit Kumar Singh and Praveensingh B. Hajeri discuss the challenges associated with siRNA and the full potential of RNAi for the development of therapeutic tools and drugs.
19 August 2010

siRNAs: their potential as therapeutic agents – Part I. Designing of siRNAs

Developing precise tools for designing siRNAs can achieve the most efficient knockdown of target genes and reduce off-target effects. Here, Praveensingh B. Hajeri and Sunit Kumar Singh discuss the strategies and parameters required for effective siRNA designing and synthesis.
18 August 2010

Aptocine-Mediated Systemic Immune Tumor Destruction: An Emerging Intratumoral Whole Cell Autologous Vaccine

This is a white paper addressing the immunotherapeutic potential of the development product Aptocine and puts it in the context of current treatments and other 'cancer vaccines' in development.
08 March 2010


02 February 2010

The shrinking of the knowledge base – what is the impact of this on the speed and security of drug development?

Paul Branthwaite discusses the implication of reducing the Pharmaceutical industry knowledge base as a result of mergers, acquisitions and a drive to reduce cost base. He specificaly deals with the impact of these changes on the ability to produce innovative pharmaceuticals and the time required so to do.
02 February 2010